Kalytera Therapeutics’ statement of loss as of September 30, 2017.

Welcome to The Deep Dive, where we focus on providing investors of Canadian junior stock markets the knowledge they need to make smart investment decisions. We take a closer look at all data relating to organizations to create quality stock analysis for investors. Not a recommendation to buy or sell securities. Always do additional research and consult a professional before purchasing a security.